Scientific Studies on Shilajit: What the Peer-Reviewed Research Says

Scientific Studies on Shilajit: What the Peer-Reviewed Research Says

Written by Dr. Sana Khalid — Clinical Nutritionist, Golden Shilajit Official Research Team. Reviewed by the Golden Shilajit Research Team.

Scientific Studies on Shilajit: What the Peer-Reviewed Research Says

Shilajit has been the subject of peer-reviewed clinical research across multiple health domains. This article summarises the key studies, their findings, and their limitations — so you can assess the evidence honestly.

Key Clinical Studies

Testosterone and Male Hormonal Health (Andrologia, 2015)

A double-blind, placebo-controlled trial in 75 healthy male volunteers aged 45–55. Participants took 250mg of purified Shilajit twice daily for 90 days. Results: significant increases in total testosterone, free testosterone, and DHEA compared to placebo. No significant adverse effects. Liver and kidney function remained within normal ranges. See: Shilajit for Testosterone: What the Science Says.

Exercise Performance (Journal of the International Society of Sports Nutrition, 2019)

A randomised controlled trial in healthy volunteers. Participants took 500mg of purified Shilajit daily for 8 weeks. Results: improved exercise performance and reduced fatigue markers compared to placebo. No significant adverse effects. See: Shilajit for Athletes.

Male Fertility (Andrologia, 2010)

A clinical study in men with oligospermia. Shilajit supplementation was associated with improvements in sperm count, motility, and morphology. The proposed mechanism involves fulvic acid’s role in mitochondrial function in sperm cells and zinc’s role in sperm production.

Cognitive Function and Alzheimer’s Research

Laboratory studies have shown that fulvic acid inhibits tau protein aggregation — a hallmark of Alzheimer’s disease — and can disaggregate existing tau filaments. These are in vitro findings and do not constitute clinical evidence of efficacy in humans. See: Fulvic Acid in Shilajit: The Complete Guide.

Limitations of the Current Evidence Base

Most clinical studies on Shilajit have been conducted in male populations, with relatively small sample sizes, and over short durations (8–90 days). Long-term safety and efficacy data is limited. The evidence base is promising but not yet comprehensive by the standards of pharmaceutical research.

Related Reading

Back to blog